This study examined circulating tumor cell (CTC) counts as measured by a novel EpCAM-independent assay and compared CTC counts with multiple known patient and tumor prognostic factors to determine the utility of pretreatment CTC levels as a preliminary prognostic biomarker for patients undergoing definitive radiation therapy (RT) for NSCLC.
Despite the success of stereotactic body radiotherapy (SBRT) as a treatment modality for early-stage non–small-cell lung cancer (NSCLC), some patients develop localized intrathoracic recurrences after treatment. Effective salvage therapy for these patients has typically been limited. We examine our institutional experience using SBRT for salvage of intrathoracic recurrence after definitive SBRT for early-stage NSCLC.
Stereotactic body radiation therapy (SBRT) has become the treatment of choice for early-stage non–small-cell lung cancers (NSCLCs) in nonoperative candidates. The purpose of this study was to examine the efficacy and toxicity of SBRT for stage T2 NSCLC.
In patients with non–small-cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT), there are few established predictors of outcomes. Pretreatment maximum standardized uptake value (SUVmax) has recently been debated as a prognosticator of progression-free survival (PFS). Here, we present a retrospective series with up to 86 months follow-up evaluating potential prognosticators of outcomes.
Five early-phase clinical trials exploring chimeric antigen receptor (CAR) T-cell therapy have been suspended temporarily in response to the deaths of 2 patients with adult B-cell acute lymphoblastic leukemia
In a phase I trial, non–small-cell lung cancer (NSCLC) patients with tumors that expressed PD-L1 had significantly better outcomes with MK-3475 therapy compared with patients with PD-L1–negative tumors.
The effectiveness of radiation treatments for patients with squamous cell cancer of the head and neck has been reviewed by an international team of researchers. They identified two biomarkers that were good at predicting a patient's resistance to radiation therapy. "While our findings are encouraging, and a step toward personalized medicine, we hope to do more of this research with a larger, randomized trial," the authors conclude.
A retrospective study has shown that two targeted therapy drugs achieved similar outcomes among people with metastatic or recurrent non-small cell lung cancer (NSCLC) harboring an EGFR mutation.
Advances in treating multiple myeloma have transformed the field over the past decade, giving clinicians more effective therapy options for newly diagnosed patients who are candidates for stem cell transplant and those who are not.
A 71-year-old woman not on hormone replacement therapy presented with uterine bleeding. Dilation and curettage revealed complex hyperplasia with atypia, focal clear-cell features, and endocervicitis. Endometrial intraepithelial carcinoma was suspected.
Scientists have successfully engineered platelet cells in dogs to express higher levels of factor VIII, paving the way for further tests in humans.
The order of the sequencing of sorafenib and sunitinib for first-line and second-line therapy did not affect progression-free and overall survival for patients with advanced renal cell carcinoma.
In the future, we also need to improve our ability to personalize the duration of endocrine therapy, with a goal of optimizing patient selection for extended therapy. Hopefully, clinical-pathologic indices and predictive biomarkers similar to the Oncotype DX 12-gene recurrence score or the PAM50 risk of recurrence score for adjuvant chemotherapy will soon emerge to guide adjuvant endocrine therapy.
To gain insight into the studies being presented at the ASH Annual Meeting, we interviewed Marcel R.M. van den Brink, MD, PhD, on abstracts being presented by faculty at Memorial Sloan-Kettering Cancer Center.
Acting ahead of schedule, the FDA has granted an accelerated approval to ibrutinib as a treatment for patients with mantle cell lymphoma who have received at least one prior therapy.
The role of transplant in MCL is in clinical evolution. Up-front high-dose therapy and autologous stem cell transplant remains an attractive option for those with chemosensitive disease regardless of the induction regimen chosen, whereas this approach in the relapsed or refractory setting has not yielded long-term disease-free intervals.
The Cancer Genome Atlas provides us with our first thorough insight into the genetic heterogeneity of squamous cell carcinoma of the lung; whether these findings will translate into personalized squamous cell lung cancer therapy is yet to be determined.
The standard of care for metastatic renal cell carcinoma (RCC) prevailed in a randomized comparison of everolimus (Afinitor) and sunitinib (Sutent) as first-line therapy
Researchers have had little success in developing an HIV cure, but recent studies involving gene therapy, immune-based therapy, reactivation of the immune system, and "very early" treatment have produced promising results.
The ratio of two protein levels may predict clinical benefit of EGFR inhibitors. Low levels of a protein called Mig6 (mitogen-inducible gene 6) and high levels of EGFR corresponded to a higher clinical response rate and progression-free survival in a small prospective cohort of lung cancer patients treated with the anti-EGFR therapy gefitinib.
A phase III trial exploring necitumumab plus chemotherapy as a first-line therapy for patients with metastatic squamous non-small cell lung cancer has demonstrated an improvement in overall survival when compared to chemotherapy alone.
The FDA approved afatinib (Gilotrif) as a first-line therapy for patients with metastatic non-small-cell lung cancer whose tumors harbor certain mutations in the epidermal growth factor receptor gene.
A two-step immunotherapy approach consisting of adoptive T-cell therapy and a dendritic cell vaccine has shown activity in a phase I advanced ovarian cancer clinical trial.
Bone metastases result in poorer outcomes for those patients with advanced renal cell carcinoma (RCC), who were treated with a molecularly targeted therapy. The results were presented in two separate analyses at the annual ASCO meeting.
Patients with chronic lymphocytic leukemia and mantle cell lymphoma showed high response rates to therapy with the novel targeted therapy ibrutinib, further solidifying the safety and efficacy of a drug that has proven very promising in early clinical trials.
Researchers observed durable responses in patients with renal cell carcinoma treated with the PD-L1 antibody MPDL3280A. The study, which was presented at the 2013 ASCO Annual Meeting, was one of the few immune therapy trials that allowed patients with non-clear cell histologies and some clinical activity was observed in these patients.
Salvage therapy combining the novel heat shock protein 90 inhibitor ganetespib with docetaxel significantly improved overall survival in some patients with non–small cell lung cancer.
A simple serum protein test can help guide treatment decisions between chemotherapy and erlotinib as second-line therapy for patients with non-small-cell lung cancer, according to results of a phase III study presented at ASCO.
Ian MacDonald, MSc, MD, talked about the future of gene therapy trials in choroideremia, a single-gene disorder that primarily affects the eye.
